Ronald S Go, Eric Jacobsen, Robert Baiocchi, Ilia Buhtoiarov, Erin B Butler, Patrick K Campbell, Don W Coulter, Eli Diamond, Aron Flagg, Aaron M Goodman, Gaurav Goyal, Dita Gratzinger, Paul C Hendrie, Meghan Higman, Michael D Hogarty, Filip Janku, Reem Karmali, David Morgan, Anne C Raldow, Alexandra Stefanovic, Srinivas K Tantravahi, Kelly Walkovich, Ling Zhang, Mary Anne Bergman, Susan D Darlow
{"title":"组织细胞肿瘤，2.2021版，NCCN肿瘤学临床实践指南。","authors":"Ronald S Go, Eric Jacobsen, Robert Baiocchi, Ilia Buhtoiarov, Erin B Butler, Patrick K Campbell, Don W Coulter, Eli Diamond, Aron Flagg, Aaron M Goodman, Gaurav Goyal, Dita Gratzinger, Paul C Hendrie, Meghan Higman, Michael D Hogarty, Filip Janku, Reem Karmali, David Morgan, Anne C Raldow, Alexandra Stefanovic, Srinivas K Tantravahi, Kelly Walkovich, Ling Zhang, Mary Anne Bergman, Susan D Darlow","doi":"10.6004/jnccn.2021.0053","DOIUrl":null,"url":null,"abstract":"<p><p>Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation (\"watch and wait\") may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":" ","pages":"1277-1303"},"PeriodicalIF":16.4000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"19","resultStr":"{\"title\":\"Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.\",\"authors\":\"Ronald S Go, Eric Jacobsen, Robert Baiocchi, Ilia Buhtoiarov, Erin B Butler, Patrick K Campbell, Don W Coulter, Eli Diamond, Aron Flagg, Aaron M Goodman, Gaurav Goyal, Dita Gratzinger, Paul C Hendrie, Meghan Higman, Michael D Hogarty, Filip Janku, Reem Karmali, David Morgan, Anne C Raldow, Alexandra Stefanovic, Srinivas K Tantravahi, Kelly Walkovich, Ling Zhang, Mary Anne Bergman, Susan D Darlow\",\"doi\":\"10.6004/jnccn.2021.0053\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation (\\\"watch and wait\\\") may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.</p>\",\"PeriodicalId\":520697,\"journal\":{\"name\":\"Journal of the National Comprehensive Cancer Network : JNCCN\",\"volume\":\" \",\"pages\":\"1277-1303\"},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"19\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Comprehensive Cancer Network : JNCCN\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.6004/jnccn.2021.0053\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Comprehensive Cancer Network : JNCCN","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6004/jnccn.2021.0053","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation ("watch and wait") may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
